Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with ...
QOO unveils new Pad5e tablet, WATCH GT 2 smartwatch, and TWS 5 earbuds, enhancing user experience with advanced features and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback